Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities
Net loss	$ (26,727)	$ (12,189)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,187	3,464
Interest accretion	440	331
Bad debt expense	499
Reversal of DOJ accrual		(350)
Mark to market on warrants	(279)	112
Stock-based compensation	1,535	2,270
Deferred income taxes	18
Change in estimate on collectability of accounts receivable	3,479
Change in fair value of contingent consideration	(44)	1,522
Other gains and expenses, net	18
Other changes in operating assets and liabilities:
Increase in accounts receivable	(961)	(3,546)
Decrease (increase) in other current assets	129	(501)
Increase in other long-term assets	(11)
(Decrease) increase in accounts payable	(835)	668
Increase in accrued salaries and bonus	482	30
Decrease in accrued liabilities	(1,341)	(402)
Increase (decrease) in long-term liabilities	454	(82)
Net cash used in operating activities	(18,957)	(8,673)
Cash Flows From Investing Activity
Acquisition of Biopharma, net of cash acquired	(13,829)
Purchase of property and equipment	(131)	(449)
Sale of property and equipment	13
Net cash used in investing activity	(13,947)	(449)
Cash Flows From Financing Activities
Issuance of common stock, net of expenses	6,478
Issuance of preferred stock, net of expenses	25,744
Payment of Seller's note	(6,024)
Borrowings on Line of Credit	3,000
Cash paid for repurchase of restricted shares	(41)	(9)
Net cash provided by (used in) financing activities	29,157	(9)
Net decrease in cash and cash equivalents	(3,747)	(9,131)
Cash and cash equivalents - beginning of year	6,068	15,199
Cash and cash equivalents - end of year	$ 2,321	$ 6,068